This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. I am delighted to ...
Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...
Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...
Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...
Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results